The safety and effectiveness of donanemab—an Alzheimer’s drug recently approved by the US Food & Drug Administration (FDA)—is called into question in an investigation published by The BMJ.
The safety and effectiveness of donanemab—an Alzheimer’s drug recently approved by the US Food & Drug Administration (FDA)—is called into question in an investigation published by The BMJ.